プレスリリース（2007/11/07）　
高脂血症治療剤｢フェノフィブラート」の糖尿病網膜症に対する効果について
−大規模臨床試験「FIELD」サブ解析結果−

プレスリリース（2005/11/16）
高脂血症治療剤｢フェノフィブラート」の2型糖尿病患者を対象にした大規模臨床試験「FIELD」の結果について−心筋梗塞等の心血管イベントを有意に抑制−

プレスリリース（2005/10/06）
高脂血症治療剤「フェノフィブラート」の2型糖尿病患者を対象にした大規模臨床試験「FIELD」について

大規模臨床試験「FIELD」の解説(音声付)

FIELD GAZETTE(3) （2005/10）

FIELD GAZETTE(2) （2005/07）

FIELD GAZETTE(1) （2005/02）

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

The FIELD study investigators:The Lancet,366(9500):1849,2005.

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

Scott R, et al.:Cardiovasc Diabetol.4:13,2005.

The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481].

The FIELD Study Investigators:Cardiovasc Diabetol,3(1):9,2004.

Design, Patient Characteristic and Run-In Responses to Treatment in FIELD: A Large-Scale Trial of Fenofibrate's Effects on Cardiovascular Disease in Type 2 Diabetes

Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes.

Leinonen ES, et al.:Diabetes Care,25(10):1807,2002.

Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy.

Keech AC, et al.:Diabet Med.22(11):1558,2005.

Determinants of carotid intima-media thickness and plaque occurrence in type 2 diabetes

Grieve SM, et al.:Atherosclerosis Supplements,4 (2):79,2003.

Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes.
.

Leinonen E, et al.:Atherosclerosis,166(2):387,2003.